FDA's consumer safety officer, Jason Chancey, detailed real inspection findings, such as taped gaskets and delayed retesting, behind sterile facility deficiencies.
|Articles|June 1, 2015
- BioPharm International-06-01-2015
- Volume 28
- Issue 6
Automated Handwashing System Increases Efficiency
Meritech’s CleanTech 2000SCA Automated Handwashing System delivers a 12-second wash and rinse cycle that removes 99.98% of dangerous pathogens from bare skin and gloves.
Advertisement
Meritech’s CleanTech 2000SCA Automated Handwashing System delivers a 12-second wash and rinse cycle that removes 99.98% of dangerous pathogens from bare skin and gloves. The compact system features a clean-in-place design and turnstile-controlled access that automatically opens at the end of each handwashing cycle.
The system requires 75% less water and soap and produces less discharge waste. A stainless-steel supporting wall and hand dryer or paper towel dispenser can be added optionally.
Meritech
Articles in this issue
over 11 years ago
Host-Cell Protein Measurement and Controlover 11 years ago
Advanced Technologies Facilitate Scale-up and Technology Transferover 11 years ago
What’s In a Name? For Biosimilars, A Lotover 11 years ago
Sterile Filtration Techniques for Optimal Microbial Retentionover 11 years ago
Quality Systems Key to Lifecycle Drug Managementover 11 years ago
Another In-House Operation Gets Outsourcedover 11 years ago
Biocompatible pH Sensor Ensures Reliabilityover 11 years ago
Your Insight Can Create Industry Benefitsover 11 years ago
BioPharm International, June 2015 Issue (PDF)over 11 years ago
Market Access Outlook for AustraliaAdvertisement
Related to this article
Guselkumab eased spinal pain, stiffness, and MRI-confirmed spinal inflammation in a 411-patient trial of psoriatic arthritis with axial involvement.
Dr Stephen Wilson, CEO of the Botnar Institute of Immune Engineering, describes Basel's collaborative ecosystem and a 3-year roadmap linking research to global clinical partners.
BIIE CEO Dr Stephen Wilson outlines rapid growth plans and a multidisciplinary technology stack targeting global clinical translation.
Dazodalibep hit its phase 3 primary endpoint at week 48, building on phase 2 data showing a 6.3-point ESSDAI reduction versus placebo.
Made Scientific's new 85,000-sq.-ft. facility, with 145 prior GMP batches, adds clinical- to commercial-scale cell therapy capacity.
Novo Nordisk reports that CagriSema outperformed tirzepatide with 12.4% weight loss versus 9.1% in a phase 3 trial in adults with type 2 diabetes.
Vironexis Biotherapeutics reported that the first three antibody-naive patients with relapsed/refractory acute lymphoblastic leukemia treated with its one-time in vivo immunotherapy VNX-101 all achieved MRD-negative complete responses, with durability tracked through at least nine months.
Advertisement
Advertisement